Abstract: This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty/oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.

Abstract: The present invention relates to a pilot tone generating method and apparatus of an orthogonal frequency division multiple access system and method, and a channel estimation method and apparatus using the same. The channel estimation apparatus includes a pilot tone extracting unit for extracting a pilot tone, which is inserted within a frame with data tone, masked with an orthogonal code; a pilot tone unmasking unit for unmasking of the pilot tone extracted from the pilot tone extracting unit by using an orthogonal code information; and a channel estimation operating unit for estimating a channel by calculating an average of the pilot tones which is unmasked in the unmasking unit.

Abstract: A powder comprising nanoparticles of a sparingly water-soluble drug prepared in accordance with the present invention exhibits enhanced bioavailability without generating adverse side effects caused by impurities, while the nano-particle size of the drug remains unchanged when administered. Accordingly, the powder can be useful for the development of a formulation of a sparingly water-soluble drug for oral and parenteral administration.

Abstract: Disclosed is a transdermal preparation containing a hydrophobic drug. As a method of continuing the high drug permeation, it is used an unique hydrophilic polymer system in which the drug can be contained in a high concentration under no water environment, a solubility of the hydrophobic drug is decreased as the water is introduced to the patch from the skin, so that the drug is maintained at the saturation concentration even though the drug content is decreased as the drug is permeated to the skin. During the application of the transdermal preparation to the skin, it is possible to continuously permeate the high amount of drug, to maintain the sufficient adhesion during the use and to minimize the skin side effect, because the hydrophilic polymer absorbs the water from the skin. The hydrophilic polymer system can serve the function thereof through the hydrophobic adhesive layer capable of preventing the water quickly absorbed from the skin from being evaporated to the outside of the patch.

Abstract: Provided are a transmission method and apparatus for allocating a subchannel and forming a stationary beam to maximize transmission efficiency in an OFDMA based wireless communication system. The method includes determining the subchannel for the equipment of each user based on the channel state of the equipment of each user, determining a beam index for the equipment of each user, based on location information and direction of arrival information of the equipment of each user, generating an OFDM symbol by mapping a modulation symbol corresponding to the equipment of each user to the determined subchannel, and transmitting the generated OFDM symbol to a wireless space by forming a beam following the determined beam index. Using the method, the equipment of each user can be allocated with an advantageous subchannel, can remove an interference signal at low cost, and can increase total throughput of an OFDMA system downlink.

Abstract: Provided are a dynamic resource allocation method and apparatus in an Orthogonal Frequency Division Multiple Access (OFDMA)-based cognitive radio system and a downlink frame structure of the method and apparatus. The method includes a base station (BS) selecting one of an Adaptive Modulation and Coding (AMC) subchannel allocation scheme, in which a subchannel comprising at least one bin comprising a first plurality of continuous subcarriers in a frequency domain, is allocated, and a diversity subchannel allocation scheme, in which a subchannel comprising a second plurality of scattered subcarriers in the frequency domain is allocated, according to a level of frequency selectivity of an unused idle frequency band; and the BS allocating at least one subchannel to a terminal according to the selected subchannel allocation scheme. Accordingly, downlink throughput in the cognitive radio system can be increased.

Abstract: The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparations according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its production is easy owing to convenience of process.

Abstract: This invention provides a pharmaceutical composition comprising a lipase inhibitor; a lipophilic oil absorbent selected from the group consisting of hydrogenated castor oil, hydrogenated vegetable oil, glyceryl behenate, glyceryl palmitostearate and a mixture thereof; and a pharmaceutically acceptable additive, an oral formulation of a lipase inhibitor prepared there from and a method for preparing said formulation. The formulation of the present invention can minimize side effects such as oily spotting, fatty/oily stool, abdominal distension and flatus, and thus it can be advantageously used for preventing or treating obesity and hyperlipaemia.

Abstract: A sustained release microparticles which is capable of releasing a protein drug continuously over a long period of time without initial burst release of the drug can be simply prepared by a method including the steps of a) dissolving a protein drug in an aqueous solution to obtain a water phase; b) dissolving sucrose acetate isobutyrate (SAIB) and a biodegradable polymer in an organic solvent to obtain an oil phase; c) adding the water phase obtained in step a) to the oil phase obtained in step b) to form a primary emulsion; and d) adding the primary emulsion to an external aqueous continuous phase to form a secondary emulsion and recovering the solid product formed in the secondary emulsion.

Abstract: A sustained-release pellet formulation comprising: a pellet core comprising an ?1-receptor antagonist, a pellet-forming substance and a pharmaceutically acceptable excipient and a coating layer comprising an enteric coating substance and a water-insoluble polymer, which is coated on said pellet core maintains a therapeutically effective drug level in the blood for a sufficient time without an initial burst and sustains the release of the drug even in the small intestine due to the water-insoluble polymer in the coating layer

Abstract: Disclosed herein is a sustained-release topiramate preparation and a method for producing the topiramate preparation. The sustained-release topiramate preparation is produced using double granules obtained by granulating topiramate or a pharmaceutically acceptable salt thereof using a solid dispersant by a solid dispersion method (first granulation), and further by granulating the granules using a release sustaining material by dry or wet granulation (second granulation).

Abstract: The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparation according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its production is easy owing to convenience of process.

Abstract: The present invention relates to polymeric microparticulates for sustained release of drug and to the process for the preparation thereof.

Abstract: The present invention relates to a film-forming agent which forms a film on the skin, and also to a preparation for percutaneous administration containing the film-forming agent and active ingredient. The transdermal preparation including the film-forming agent of the present invention and active ingredient exhibits excellent elasticity and flexibility, shows superior adhesion power when formed on the skin, and forms non-sticky film.

Abstract: The present invention relates to a film-forming agent which forms a film on the skin, and also to a preparation for percutaneous administration containing the film-forming agent and active ingredient. The transdermal preparation including the film-forming agent of the present invention and active ingredient exhibits excellent elasticity and flexibility, shows superior adhesion power when formed on the skin, and forms non-sticky film.

Abstract: A multi-stage oral drug controlled-release system is disclosed, as well as a preparation for maintaining the drug blood concentration at a desired level for a prolonged time. The system operates by releasing the drug at a constant rate through stepwise control of drug release following administration of the preparation. More specifically, the multi-stage oral drug controlled-release system involves the stepwise release of drug-containing granules from an inner matrix, which is surrounded by a coating or release-modifying layer. The granules contain an active drug and a carrier material in size of 0.1˜1 mm. The carrier material is hydrophobic when the drug has a water-solubility of 1 mg/ml or more, and is hydrophilic when the drug has a water-solubility of less than 1 mg/ml. The inner matrix, in which the drug-containing granules are embedded, is formed from swelling and erodible polymer(s) and swelling-regulating material(s).

Abstract: A pharmaceutical composition formulated for sustained release is disclosed. In one embodiment, the pharmaceutical composition comprises cyclosporin and a release modifier encapsulated in a biodegradable polymer. In a preferred embodiment, the release modifier is selected from the group consisting of hydrophilic release modifiers, lipophilic release modifiers, and combinations thereof. Most preferably, the release modifier comprises at least one hydrophilic release modifier and at least one lipophilic release modifier.

Abstract: According to the method, an aqueous salt solution containing either tin, indium or both, are mixed with an alkali to produce a slurry containing precipitated particles. Then, the slurry is maintained at a predetermined temperature range for a time sufficient to convert the precipitated particles to larger size particles by coagulation or agglomeration. The resulting slurry is then dried and calcined to produce a mixed power. The mixed power is ball milled, press molded and/or cold isostatic press (CIP) molded. The molded body is then sintered to form an ITO sintered body. The ITO sintered body obtained by this process offers superior sinterability whose theoretical density can reach more than 95%.